Found: 5
Select item for more details and to access through your institution.
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 5, p. 945, doi. 10.1007/s00432-018-2604-x
- By:
- Publication type:
- Article
A Multicenter, Randomized Phase 3 Study of Asciminib (ABL001) vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 TKIs.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S286, doi. 10.1016/j.clml.2019.07.230
- By:
- Publication type:
- Article
ENESTfreedom 144-Week Update: Long-Term Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S226, doi. 10.1016/j.clml.2018.07.099
- By:
- Publication type:
- Article
Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S223, doi. 10.1016/j.clml.2018.07.094
- By:
- Publication type:
- Article
Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 1, p. 219, doi. 10.1007/s00280-012-1999-3
- By:
- Publication type:
- Article